

**FEDERAL MARITIME COMMISSION****Sunshine Act Meeting**

**AGENCY HOLDING THE MEETING:** Federal Maritime Commission.

**TIME AND DATE:** September 20, 2017; 10:00 a.m.

**PLACE:** 800 N. Capitol Street NW., First Floor Hearing Room, Washington, DC.

**STATUS:** The meeting agenda originally published September 18, 2017, 82 FR 43541, is revised to add item 2 in the Open Session. The change was made upon a unanimous vote of the Commission. Parts of this meeting will be open to the public and streamed live at <http://fmc.capitolconnection.org/>. The rest of the meeting will be closed to the public.

**MATTERS TO BE CONSIDERED:****Portions Open to the Public**

1. Briefing by Commissioner Dye on the Supply Chain Innovation Teams and Update from Global Liner Shipping Asia Conference.

2. Updates from Acting Chairman Khouri on United States—European Union and United States—United Kingdom Maritime Bilateral Discussions and London International Shipping Week.

3. Staff Briefing on Review Process for Carrier and Marine Terminal Operator Agreements.

**Portions Closed to the Public**

1. Staff Update on Petition of the Coalition for Fair Port Practices (P4–16).

**CONTACT PERSON FOR MORE INFORMATION:** Rachel E. Dickon, Assistant Secretary, (202) 523 5725.

**Rachel E. Dickon,**

*Assistant Secretary.*

[FR Doc. 2017–20344 Filed 9–19–17; 4:15 pm]

**BILLING CODE 6731-AA-P**

**FEDERAL RESERVE SYSTEM****Formations of, Acquisitions by, and Mergers of Bank Holding Companies**

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The applications will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than October 18, 2017.

*A. Federal Reserve Bank of Philadelphia* (William Spaniel, Senior Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105–1521. Comments can also be sent electronically to [Comments.applications@phil.frb.org](mailto:Comments.applications@phil.frb.org):

1. *Meridian Corporation*, Malvern, Pennsylvania; to become a bank holding company by acquiring 100 percent of the voting shares of Meridian Bank, Malvern, Pennsylvania.

*B. Federal Reserve Bank of Atlanta* (Chapelle Davis, Assistant Vice President) 1000 Peachtree Street NE., Atlanta, Georgia 30309. Comments can also be sent electronically to [Applications.Comments@atl.frb.org](mailto:Applications.Comments@atl.frb.org):

1. *Robertson Holding Company, L.P., and Unified Shares, LLC and Commercial Bancgroup*, all of Harrogate, Tennessee; to acquire 100 percent of the voting shares of Citizens Bancorp, Inc., and thereby indirectly acquire Citizens Bank, both of New Tazewell, Tennessee.

Board of Governors of the Federal Reserve System, September 18, 2017.

**Yao-Chin Chao,**

*Assistant Secretary of the Board.*

[FR Doc. 2017–20132 Filed 9–20–17; 8:45 am]

**BILLING CODE 6210-01-P**

**FEDERAL TRADE COMMISSION****SES Performance Review Board**

**AGENCY:** Federal Trade Commission.

**ACTION:** Notice.

**SUMMARY:** Notice is hereby given of the appointment of members to the FTC Performance Review Board.

**FOR FURTHER INFORMATION CONTACT:**

Vicki Barber, Chief Human Capital Officer, 600 Pennsylvania Avenue NW., Washington, DC 20580, (202) 326–2700.

**SUPPLEMENTARY INFORMATION:**

Publication of the Performance Review Board (PRB) membership is required by 5 U.S.C. 4314(c)(4). The PRB reviews and evaluates the initial appraisal of a senior executive's performance by the supervisor, and makes recommendations regarding performance ratings, performance awards, and pay-for-performance pay adjustments to the Chairman.

The following individuals have been designated to serve on the Commission's Performance Review Board:

David Robbins, Executive Director, Chairman  
David Shonka, Acting General Counsel  
Marian Bruno, Deputy Director, Bureau of Competition  
Thomas Pahl, Acting Director, Bureau of Consumer Protection  
Michael Vita, Acting Director, Bureau of Economics

By direction of the Commission.

**Donald S. Clark,**

*Secretary.*

[FR Doc. 2017–20077 Filed 9–20–17; 8:45 am]

**BILLING CODE 6750-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Centers for Disease Control and Prevention****Board of Scientific Counselors, Office of Public Health Preparedness and Response, (BSC, OPHPR)**

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of meeting.

**SUMMARY:** In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), announces the following meeting for the Board of Scientific Counselors, Office of Public Health Preparedness and Response, (BSC, OPHPR). This meeting is open to the public, limited only by the space available. The meeting room accommodates up to 75 people. Public participants should pre-register for the meeting as described below.

Members of the public that wish to attend this meeting in person should pre-register by submitting the following information by email, facsimile, or phone (see Contact Person for More Information) no later than 12:00 noon (EDT) on Tuesday, October 23, 2017:

- Full Name
- Organizational Affiliation
- Complete Mailing Address
- Citizenship
- Phone Number or Email Address

The public is also welcome to listen to the meeting via Adobe Connect. Pre-registration is required by clicking the links below.

*WEB ID for October 30, 2017:* (100 seats) <https://adobeconnect.cdc.gov/e7yrlzismvq/event/registration.html>.

*WEB ID for October 31, 2017:* (100 seats) <https://adobeconnect.cdc.gov/e4icit9ctcz/event/registration.html>.

*Dial in number:* 888-324-3809 (100 seats).

*Participant code:* 3293468.

**DATES:** The meeting will be held on October 30, 2017, 10:00 a.m. to 5:00 p.m., ET; October 31, 2017, 8:30 a.m. to 3:30 p.m., ET.

**ADDRESSES:** Centers for Disease Control and Prevention (CDC), Global Communications Center, Building 19, Auditorium B3, 1600 Clifton Road NE., Atlanta, Georgia 30329.

**FOR FURTHER INFORMATION CONTACT:** Dometa Ouisley, Office of Science and Public Health Practice, Centers for Disease Control and Prevention, 1600 Clifton Road NE., Mailstop D-44, Atlanta, Georgia 30329, Telephone: (404) 639-7450; Facsimile: (404) 471-8772; Email: [OPHPR.BSC.Questions@cdc.gov](mailto:OPHPR.BSC.Questions@cdc.gov).

**SUPPLEMENTARY INFORMATION:**

*Purpose:* This Board is charged with providing advice and guidance to the Secretary, Department of Health and Human Services (HHS), the Assistant Secretary for Health (ASH), the Director, Centers for Disease Control and Prevention (CDC), and the Director, Office of Public Health Preparedness and Response (OPHPR), concerning strategies and goals for the programs and research within OPHPR, monitoring the overall strategic direction and focus of the OPHPR Divisions and Offices, and administration and oversight of peer review for OPHPR scientific programs. For additional information about the Board, please visit: <http://www.cdc.gov/phpr/science/counselors.htm>.

*Matters To Be Considered:* The agenda for day one of the meeting will include discussions that will cover briefings and BSC deliberation on the following topics: Interval updates from OPHPR Divisions and Offices; updates from the Biological Agent Containment working group; overview of OPHPR division roles and responsibilities during complex emergencies; and Preparedness Updates from Liaison Representatives.

Day two of the meeting will cover briefings and BSC deliberation on the following topics: OPHPR Office of Policy, Planning and Evaluation Stories Project; Public Health Preparedness and Response Social Media and Communications Metrics; Incident Management Training Development Program updates, OPHPR Practice-based Research Agenda and Synthesis and Translation of Public Health Preparedness and Response Research. Agenda items are subject to change as priorities dictate.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Claudette Grant,**

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 2017-20082 Filed 9-20-17; 8:45 am]

**BILLING CODE 4163-19-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Centers for Disease Control and Prevention**

[30Day-17-17ADR]

**Agency Forms Undergoing Paperwork Reduction Act Review**

The Centers for Disease Control and Prevention (CDC) has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The notice for the proposed information collection is published to obtain comments from the public and affected agencies.

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address any of the following: (a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (c) Enhance the quality, utility, and clarity of the information to be

collected; (d) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses; and (e) Assess information collection costs.

To request additional information on the proposed project or to obtain a copy of the information collection plan and instruments, call (404) 639-7570 or send an email to [omb@cdc.gov](mailto:omb@cdc.gov). Direct written comments and/or suggestions regarding the items contained in this notice to the Attention: CDC Desk Officer, Office of Management and Budget, Washington, DC 20503 or by fax to (202) 395-5806. Written comments should be received within 30 days of this notice.

**Proposed Project**

Study to Explore Early Development, Teen Follow-Up Study (SEED Teen)—New—National Center on Birth Defects and Developmental Disabilities (NCBDDD), Centers for Disease Control and Prevention (CDC).

**Background and Brief Description**

Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impairments in social interaction and communication and stereotyped behaviors and interests. The U.S. prevalence of ASD is estimated at 1% to 2%. In addition to the profound, lifelong impacts on individuals' functioning given the core deficits in social-communication abilities, a high proportion of children with ASD also have one or more other developmental impairments such as intellectual disability or attention-deficit-hyperactivity-disorder and children with ASDs have higher than expected prevalences of health conditions such as obesity, asthma and respiratory disorders, eczema and skin allergies, migraine headaches, and gastrointestinal symptoms and disorders.

Historically, young children have been the focus of ASD research: Diagnosis and symptom detection at young ages, prenatal or early-life risk factors, and the effect of early intervention programs. Meanwhile, the number of children diagnosed with ASD each year has steadily increased and, as children age, the prevalence of adults diagnosed with ASD will likewise increase for several decades. Despite this ongoing demographic shift—which some have called “the autism tsunami”—there has been relatively